 |
|
|
Tetracaine
|
|
| Systematic (IUPAC) name | |
| 2-(dimethylamino)ethyl 4-(butylamino)benzoate | |
| Identifiers | |
| CAS number | 136-47-0 (hydrochloride) |
| ATC code | C05 D04 N01 S01 |
| PubChem | |
| Chemical data | |
| Formula | C15H24N2O2 |
| Mol. mass | 264.363 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 75.6 |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Rx Only |
| Routes | Topical, Epidural, Spinal |
 (what is this?) (verify) |
|
Tetracaine (INN, also known as amethocaine; trade name Pontocaine) is a potent local anesthetic of the ester group. It is mainly used topically in ophthalmology and as an antipruritic, and it has been used in spinal anesthesia.
In biomedical research, tetracaine is used to alter the function of calcium release channels (ryanodine receptors) that control the release of calcium from intracellular stores. Tetracaine is an allosteric blocker of channel function. At low concentrations, tetracaine causes an initial inhibition of spontaneous calcium release events, while at high concentrations, tetracaine blocks release completely[1].
References
- ^ Györke, S; Lukyanenko, V et al. (1997). Dual effects of tetracaine on spontaneous sodium release in rat ventricular myocytes. 500. J Physiol. pp. 297–309.
|
|||||||||||
|
||||||||
|
||||||||||||||||||||||
deTetracain
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
